Protein degraders and molecular glue degraders have certainly been a very hot topic of late.  One company we have been following for a while in this niche is Watertown, MA based C4 Therapeutics, who have a growing pipeline of early stage agents in development.

Setting sights on new horizons

Last year we talked with them about various strategic topics such as what makes a great target for a protein degrader and other stories.

This time around it’s time to move the discussion along by looking forward to the future and explore why the science behind their pipeline will set them up for future success in the clinic.

Obviously this isn’t guaranteed in oncology R&D and degraders are certainly not the easiest approach technically, yet they do offer a lot of potential.

In our latest expert interview we talk in detail about the C4 degrader pipeline and how they have gone about optimising their molecules for clinical performance…

BSB subscribers can read up on our ongoing commentary and analysis from the JPM conference – you can either log-in or click to access the back story behind the latest innovations.

This content is restricted to subscribers

Posted by